“Bio-buck” Deals A Good Risk-Sharing Strategy, Pharma Execs Say At BIO
Executive Summary
Bio-buck deals, those back-end-loaded, early-stage collaborations that grab headlines because of the big dollars promised, are a win-win risk share, big pharma execs say